JCR Pharmaceuticals
Financials
Estimates*
JPY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 30.1b | 51.1b | 34.3b | 42.9b | 41.6b | 41.3b | 41.8b |
% growth | 21 % | 70 % | (33 %) | 25 % | (3 %) | (1 %) | 1 % |
EBITDA | 10.5b | 22.5b | 7.5b | 10.5b | 8.9b | 7.8b | 7.7b |
% EBITDA margin | 35 % | 44 % | 22 % | 25 % | 22 % | 19 % | 18 % |
Profit | 6.9b | 14.5b | 3.8b | 5.5b | 4.9b | 4.7b | 5.2b |
% profit margin | 23 % | 28 % | 11 % | 13 % | 12 % | 11 % | 12 % |
EV / revenue | 14.5x | 5.2x | 5.4x | 2.6x | 2.0x | 2.0x | 2.0x |
EV / EBITDA | 41.6x | 11.8x | 24.9x | 10.6x | 9.3x | 10.6x | 10.6x |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Seed | ||
N/A | N/A | IPO | |
Total Funding | - |
Recent News about JCR Pharmaceuticals
EditJCR Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for rare and intractable diseases. Operating primarily in the healthcare and biotechnology sectors, JCR Pharmaceuticals serves patients, healthcare providers, and research institutions. The company's business model focuses on leveraging advanced cell and gene therapy technologies to create effective and targeted treatments. Revenue is generated through the sale of proprietary drugs, licensing agreements, and collaborative research partnerships. JCR Pharmaceuticals aims to address unmet medical needs by providing cutting-edge solutions that improve patient outcomes and quality of life.
Keywords: biopharmaceutical, rare diseases, intractable diseases, cell therapy, gene therapy, healthcare, biotechnology, innovative treatments, patient outcomes, research partnerships.